O
Orakl Oncology
Tumor avatars to transform oncology drug development
About Orakl Oncology
Orakl Oncology is a cutting-edge startup that operates in the healthcare industry, specifically in the field of oncology. The company leverages artificial intelligence (AI) to analyze a combination of experimental and patient data, providing unique insights into cancer biology. This data-driven approach allows Orakl Oncology to create tumor models that closely mimic real-life responses to drugs, a critical factor in the development of personalized medicine.
Read full description
Orakl Oncology's primary clients are other businesses within the oncology industry. The company partners with these entities to help them meet the challenges of personalized medicine, a growing trend in healthcare that tailors treatment to individual patients based on their unique genetic and health profiles.
The business model of Orakl Oncology is likely based on a B2B (business-to-business) model, where they provide their AI-powered analysis and tumor modeling services to other companies in the oncology field. The company generates revenue by charging for these services, which can help their clients develop more effective and personalized cancer treatments.
The team at Orakl Oncology is led by experienced researchers and engineers, who have been recognized for their contributions to cancer biology. Their interdisciplinary approach, combining AI, biology, and patient data, sets them apart in the field of oncology.
At a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Paris, France
- Employees
- 38
- Open positions
- 11
- Dealroom signal
- 90.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Core AI, Spinout, AI Drug Discovery, biotech medtech and e-health, Observatoire Deeptech
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Dec 2024 | $12M | $48M | Bpifrance · Singular | ↗ |
| SEED✓Equity / VC | Oct 2023 | $3.3M | $13M | Verve Ventures · HCVC · Speedinvest | ↗ |
Growth signals
Latest recorded traffic for Orakl Oncology is 3.3K monthly website visits, up 432.3% over the last three months. Orakl Oncology's team grew 40.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Speedinvest
Verve Ventures
HCVC
Singular
Bpifrance
Other known investors6 additional known investors
HEC Paris
École Polytechnique - IP Paris
HEC Challenge+
IP Paris
Agoranov
SISTAFUND
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Orakl Oncology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Orakl Oncology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.